T uberculosis is a leading cause of infectious disease mortality worldwide. Control of the intracellular growth of Mycobacterium tuberculosis (Mtb) 4 depends upon the acquisition of a robust adaptive cellular immune response. In both animal models and human tuberculosis, there is abundant evidence to support complementary roles for both CD4 ϩ and CD8 ϩ T cellmediated immunity (1) .
Mtb is a facultative intracellular pathogen that, following phagocytosis by a macrophage or dendritic cell (DC), resides in an arrested phagosome (2, 3) . Although this compartment has been traditionally thought to be a part of the vesicular, MHC-class II processing pathway, both human and mouse Mtb-specific CD8 ϩ T cells are capable of recognizing Mtb-infected cells.
Phagocytosis of particulate Ags and apoptotic cells by DCs and macrophages leads to MHC class-I (MHC-I) Ag processing and presentation through a process termed cross-presentation. Several models have been proposed to account for presentation of these Ags in a MHC-I-dependent manner. In the vacuolar model, peptides are generated in a vesicular acidic compartment and then loaded onto recycled MHC (4, 5) . Presentation of these Ags does not require endoplasmic reticulum (ER)-Golgi transport brefeldin A (BFA) independent, and is independent of TAP. In this regard, polylactide-coglycolide (PLG)-associated Ag can be delivered to the vacuolar pathway in a cathepsin-S-dependent and TAP-independent manner (6) . Conversely, particulate Ags have also been shown to be presented via a cytosolic pathway that is TAP dependent and requires proteasomal processing (7) . In these examples, the identical Ag (OVA) could be targeted to distinct processing pathways by varying the nature of the particle.
The mechanisms by which Mtb-derived Ag gain access to the MHC-I pathway are incompletely understood. Infection with live, but not heat-killed, Mtb facilitates the MHC-I-dependent recognition of soluble OVA in a TAP-dependent manner (8) . Similarly, macrophage phagosomes containing live bacillus Calmette-Guerin (BCG) appear to be porous to molecules of Ͻ70 kDa (9) . Mtb lipids and lipoproteins, actively trafficked in phagosomally derived vesicles (10) , are cross-presented by bystander APC in a TAPindependent and proteosome-independent manner (11) (12) (13) . We have reported previously that presentation to HLA-E-restricted, Mtb-specific, human CD8 ϩ T cells requires proteasomal Ag processing and is not blocked by BFA (14) . Similarly, Canaday et al. (15) developed Mtb-specific CD8 ϩ T cell lines that were insensitive to BFA blockade.
To delineate the processing pathway used by Mtb-infected cells to present to CD8 ϩ T cells, we developed a model system to test whether Mtb-infected cells preferentially use the cytosolic or vacuolar pathways. In this study, Mtb Ag was delivered to the cytosolic or vacuolar pathways by adenovirus or PLG microspheres, respectively, and human CD8 ϩ T cell clones (16) were used to monitor Ag presentation in the presence of Ag-processing inhibitors. Using this approach, we find that entry of Mtb-derived secreted proteins does not depend upon the vacuolar pathway.
Materials and Methods

Human subjects
Subjects were recruited from employees at Harborview Medical Center, Fred Hutchinson Cancer Research Center, Corixa, and Oregon Health and Science University. Protocols for venipuncture and apheresis were Institutional Review Board approved.
Cell lines and T cell clones
Clone 1-1B is an HLA-B44-restricted CD8 ϩ T cell clone specific for Mtb Ag, CFP10 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] , and recognizes the minimal epitope, AEMKTDAATL (16) . Clone 38.1-1 is a CD4 ϩ T cell clone specific for CFP10 73-87 and recognizes the epitope STNIRQAGVQYSRAD (17) . Clone A3 is an HLA-B3514-restricted CD8 ϩ T cell clone specific for the Mtb-Ag Mtb8.4 [33] [34] [35] [36] [37] [38] [39] [40] [41] and recognizes the epitope ASPVAQSYL (our unpublished observation).
mAbs and reagents
Culture medium consisted of RPMI 1640 supplemented with 10% FBS (BioWhittaker), 50 g/ml gentamicin sulfate (BioWhittaker), and 2 mM glutamine (Invitrogen Life Technologies). Human T cell assays were performed with RPMI 1640 supplemented with 10% human serum (HS), as described previously (14) . Mtb strain H37Rv was obtained from American Type Culture Collection and grown in modified Middlebrook 7H9 medium (Difco). Recombinant (18) and CFP10/Mtb11 were prepared, as described previously (19) . Adenovirus-expressing ICP47 was provided by D. Johnson (Oregon Health and Science University, Portland, OR) (20) .
Assays for T cell function
IFN-␥ ELISPOT was performed, as described (16) . Human and murine IFN-␥ ELISAs and proliferation assays were performed, as described (14, 18) .
Microsphere preparation
PLG RG502H was purchased from Boehringer Ingelheim. Polyvinyl alcohol (87-89% hydrolyzed; 13-23,000 kDa) was purchased from SigmaAldrich. PLG polymer was dissolved in dichloromethane and emulsified using a Silverson homogenizer. Microspheres were hardened for 2 h with mild stirring, washed twice via centrifugation, and lyophilized after the addition of mannitol. Protein was adsorbed to the microspheres at the time of use. The lyophilized microspheres were dispersed in aqueous buffer, to which the protein solution was added and gently mixed. Microspheres were collected by centrifugation with the unadsorbed protein solution removed. Protein adsorption to the microspheres was quantified by HPLC analysis of the supernatant before and after adsorption and confirmed for select lots by amino acid analysis on the microsphere formulation.
Expansion of T cell clones
To expand the CD8 ϩ T cell clones, a rapid expansion protocol using anti-CD3 mAb stimulation was used (21) . T cell clones were cultured in the presence of irradiated allogeneic PBMC (25 ϫ 10 6 ), irradiated allogeneic lymphoblastoid cell line (5 ϫ 10 6 ), and anti-CD3 mAb (30 ng/ml; Chiron) in RPMI 1640 medium with 10% HS in a T-25 upright flask in a total volume of 30 ml. The cultures were supplemented with IL-2 (1 ng/ml; Chiron) on days ϩ1, ϩ4, ϩ7, and ϩ10 of culture. The cell cultures were washed on day ϩ4 to remove remaining soluble anti-CD3 mAb.
Generation of peripheral blood DCs and macrophages
Monocyte-derived DC were prepared according to the method of Romani et al. (22) . Briefly, PBMC were isolated from heparinized blood by centrifugation over Ficoll-Hypaque (Sigma-Aldrich) and washed three times with culture medium. Alternatively, PBMC were obtained via leukapharesis. Cells were resuspended in 2% HS medium (BioWhittaker) and allowed to adhere to a T-75 (Costar) flask at 37°C for 1 h in the presence of 30 g/ml DNase (Amgen). After gentle rocking, nonadherent cells were removed, and 30 ml of 10% HS medium containing 10 ng/ml IL-4 (Amgen) and 10 ng/ml GM-CSF (Amgen) was added. After 5-7 days, cells were harvested with cell-dissociation medium (Sigma-Aldrich). To generate Mtb-infected cells, 1 ϫ 10 6 phagocytes were cultured overnight in the presence of Mtb (H37Rv; multiplicity of infection (MOI) 25-50) in lowadherence 16-mm wells (Costar no. 3473). After 18 h, the cells were harvested and resuspended in RPMI 1640/10% HS. Infection with these MOIs typically leads to at least one bacteria per cell, but does not result in cellular apoptosis (14, 23) .
Metabolic inhibition of Ag presentation
One hour before the addition of Mtb to DC, lactacystin (40 M; EJ CoreyHarvard Biolabs), N-acetyl-Leu-Leu-norleucinal (LLnL; Calbiochem), or BFA (Sigma-Aldrich) was added to the culture medium. After 18 h of coincubation with Mtb, cells were harvested and fixed in either 1% paraformaldehyde (Sigma-Aldrich) or 0.1% glutaraldahyde (grade I, 25% aqueous; Sigma-Aldrich). After vigorous washing, fixed DC were used as stimulators for CD8 ϩ T cells, as described above.
Construction of adenoviral vectors
To construct the adenoviral vector expressing CFP10, the open reading frame of CFP10 was subcloned from pcDNA3/IL-1/Mtb39 and pEGFP-N1, respectively, into the multiple cloning site of the adenoviral shuttle vector, pAD1. Shuttle vectors were then cotransfected into human 293 cells with plasmid, pBGHE3 (Microbix Biosystems). Virus was purified over two CsCl gradients and titered before use.
Adenovirus infection of APC
To generate adenovirally infected APC, DC were harvested after 18 h of culture, and 5 ϫ 10 5 DC were seeded in Optimem (125 ml; Invitrogen Life Technologies) into low-adherence 16-mm wells (Costar). Adenoviral liposomes were prepared by coincubating the adenovirus and lipofectamine (6 g/ml; Invitrogen Life Technologies) for 15 min and then added to the DC cultures. After 4 -6 h, fresh medium (1 ml) containing GM-CSF (10 ng/ml) and IL-4 (10 ng/ml) was added (24) . 
Intracellular cytokine staining
Results
Presentation of adenovirally expressed CFP10 is blocked by both BFA and the proteasomal blocker LLnL
Viral Ags are expressed in the cytosol, and then processed for presentation by MHC-I via a TAP-dependent and BFA-sensitive pathway. To validate that BFA distinguishes between the vacuolar and cytosolic pathways in our in vitro system, we used a recombinant adenovirus expressing the Mtb protein CFP10. HLA-B44-positive DC were infected with CFP10 adenovirus using lipofectamine. As a control, we used a 10-mer peptide previously shown to be the minimal epitope within CFP10 recognized by the CD8 ϩ T cell clone, 1-1B (CFP10 2-11 ) (16) . Both the CFP10 2-11 peptide-pulsed DC and the CFP10 adenovirus-infected DC induced a strong IFN-␥ response by the 1-1B T cells (Fig. 1A) . However, while the addition of BFA had no effect on the recognition of peptide-pulsed APC, it resulted in complete abrogation of Ag presentation by adenovirus-infected DC. Furthermore, as is demonstrated in Fig. 1A , treatment with proteasomal blocker LLnL abrogated recognition by the 1-1B T cell clone. In contrast, identical treatment had no effect on recognition of peptide-pulsed APC.
PLG microsphere delivery of Ag is both BFA and TAP independent
Initially, we assessed whether DC pulsed with PLG-CFP10 microspheres showed enhanced Ag presentation compared with DC pulsed with soluble CFP10. DC pulsed with PLG-CFP10 microspheres, when compared on a microgram per microgram basis, are ϳ300-fold more efficient at delivering CFP10 protein to 1-1B T cells compared with soluble CFP10 (Fig. 1B) . As is demonstrated in Fig. 1C , treatment with BFA, even at the lowest concentration of BFA tested (0.16 g/ml), completely abrogated recognition of adenovirally presented CFP10, but had no effect on recognition of microsphere-presented Ag or on targets loaded with cognate peptide CFP10 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .
Ag presentation by Mtb-infected DC is blocked by both BFA and lactacystin
We next sought to determine which pathway was used for presentation of CFP10 to 1-1B T cells during the course of infection of FIGURE 1. Cytosolic and vacuolar Ag presentation can be distinguished by sensitivity to BFA and proteasomal blockade. A, DC were pretreated with LLnL (30 M) or BFA (5 g/ml) and infected with adenoviral CFP10 overnight (MOI 100), before fixing in 0.2% paraformaldehyde. APC were then coincubated with 1-1B T cells, and IFN-␥ was assessed by ELISA after 48 h of incubation. Each bar represents the mean of triplicate cultures, and the data are representative of two separate experiments. B, Recombinant CFP10, PLG CFP10, and the cognate peptide CFP10 2-11 were tested for their ability to stimulate the CFP10-specific CD8 ϩ T cell clone 1-1B. DC (20,000) were coincubated with 1-1B T cells (20, 000) in the presence of Ag at the concentrations indicated. Plates were cultured for 48 h, after which 50 l was removed for assessment of IFN-␥ by ELISA. The plates were then pulsed with [ 3 H]thymidine (1 Ci/well). After culture for an additional 18 h, tritium uptake was determined. Each point reflects the mean of triplicate cultures, and data are representative of three separate experiments. C, DC were pretreated with titrating concentrations of BFA for 30 min and then infected with CFP10-expressing adenovirus or cocultured with CFP10 PLG microspheres. After overnight culture, DC were harvested, fixed in 0.2% paraformaldehyde, and used to stimulate 1-1B T cells. Each point reflects the mean of triplicate cultures, and data are representative of three separate experiments.
DC with Mtb. Treatment of Mtb-infected monocyte-derived DC with either BFA or the proteasomal blocker lactacystin abrogated recognition of these DC over a wide range of MOIs (Fig. 2) , suggesting that the cytosolic pathway is preferentially used by Mtbinfected cells presenting Ag to HLA-I-restricted CD8 ϩ T cells.
Ag presentation by Mtb-infected DC is blocked by the TAP inhibitor ICP47
To determine the TAP dependence of Mtb-derived Ag, the TAP inhibitor ICP47 was expressed in an adenoviral vector (20) . Expression in human monocyte-derived DC resulted in a modest reduction in cell surface expression of HLA-I without affecting HLA-II expression levels (data not shown). Monocyte-derived DC infected with adenoviral ICP47 for 30 h were then infected with Mtb, and then assessed for their ability to present to the HLA-I-restricted CD8 ϩ T cell clone 1-1B as well as to the HLA-II-restricted, CFP10-specific CD4 ϩ T cell clone 38-1.1 (25) . Expression of ICP47 abrogated the HLA-I-mediated recognition of Mtb-derived CFP10 (Fig. 3A) , but had no effect on the recognition of APC pulsed with cognate peptide (Fig. 3B) . Conversely, expression of ICP47 had no effect on the HLA-II-dependent recognition of Mtb-infected DC (Fig. 3D) or on the recognition of recombinant Ag (Fig. 3E) . Because the recognition of Mtb-infected cells was relatively inefficient, the experiment was repeated using flow cytometric analysis of Ag-dependent IFN-␥ release. As is demonstrated in Fig. 3 , C and F, treatment with ICP47 inhibited IFN-␥ release for the CFP10-specific CD8 ϩ , but not CD4 ϩ T cell clones. Furthermore, the effect was not contingent on the relatively high MOI used as it was seen at MOIs of both 25 and 50. Hence, these data demonstrate the involvement of TAP in the processing and presentation of CFP10 to HLA-I-restricted T cells.
Access of Ag to the HLA-I pathway does not require the region of deletion (RD1) secretory pathway
Comparative analysis of Mtb and BCG strains has shown that one region, RD1, is present in all strains of Mtb and absent from all strains of BCG (26 -28) . Previous reports have demonstrated that the RD1 proteins, which includes CFP10 and ESAT-6, constitute a novel secretory pathway that may have effects on membrane permeability (17, 29 -31) . Additionally, reports have demonstrated that abrogation of any member of the RD1 family can abolish secretion of ESAT-6 and CFP10. As a result, we postulated that the Mtb-derived heterodimer CFP10/ESAT-6 could form a phagosomal pore allowing for the Mtb-dependent egress of Ags into the cytosol. Because secretion of CFP10 depends on the presence of an intact RD1 region, we used a Mtb8.4 32-40 -specific, HLA-B3514-restricted T cell clone, A3, derived from an actively Mtbinfected subject (D. Lewinsohn, unpublished data). Like CFP10, recognition of Mtb-derived Mtb8.4 was blocked by both BFA and lactacystin (data not shown). Mtb mutants containing deletion of the RD1 region, or deletion of or transposon insertion in its individual gene family members (CFP10 and ESAT-6), did not abrogate recognition of the Mtb Ag Mtb8.4 (Fig. 4) . Similarly, the complemented strains appeared very similar to the original knockout. These data argue that cytosolic access of Mtb-derived Ags does not rely on an intact RD1 region.
Discussion
It has been reported previously that Mtb-derived Ags can gain access to the HLA-I pathway via either cytosolic (8, 9) or vacuolar (15) pathways. However, each of these reports had significant limitations. Mazzaccaro et al. (8) were able to demonstrate TAP-dependent and BFA-inhibitable recognition that required viable Mtb, using OVA codelivered in soluble form with Mtb. In the report by Teitelbaum et al. (32) , size-dependent colocalization of fluorescent markers with phagosomal Mtb was demonstrated following microinjection into the cytosol. In neither case, however, was processing or presentation of Mtb-derived Ag directly demonstrated. Conversely, in the report by Canaday et al. (15) , recognition of a Mtb-specific CD8
ϩ T cell line was demonstrated to be refractory to treatment with BFA, although the sensitivity to proteasomal blockade was not reported. Neither the antigenic specificity nor HLA restriction of the cell line was determined. We have demonstrated previously that HLA-E-restricted T cell clones use a pathway that is dependent on the proteasome, but refractory to BFA blockade (14) . In this study, we demonstrate that blockade with BFA can clearly distinguish the vacuolar from cytosolic pathways for the Mtb-derived Ag CFP10. Using this model, we find that recognition of Mtb Ag CFP10 is completely blocked by BFA, depends upon the proteasomal degradation, and uses TAP. Hence, these data demonstrate HLA-I-dependent presentation of Mtb-derived CFP10 does not use the vacuolar pathway. In contrast, we confirm that class I presentation of PLG-Ag microspheres is insensitive to BFA. Furthermore, we demonstrate that RD1 gene family members are not required for access of the secreted Ag Mtb8.4 into the HLA-I pathway.
It has been demonstrated recently that ER-phagosomal fusion results in a functional, MHC-I processing compartment (33, 34) . This pathway has been demonstrated to be TAP dependent, and is only partially inhibited by BFA. Our data do not distinguish between phagosomal reuptake or ER loading of proteasomally derived peptides once Mtb-derived Ags access the cytosol.
Certain Ags and lipids from Mtb have been demonstrated to gain access to vesicles that can be actively exported (35) , and these vesicles contain lipoproteins that can sensitize bystander APC in a TAP-independent fashion (11). Cross-presentation by these vesicles may be the result of apoptosis, and can result in cross-presentation in both human and mouse DC (12, 13) . Termed the detour pathway, this process requires phagosomal acidification, but not proteasomal degradation. Although we have demonstrated previously that heavily infected cells are preferentially recognized by both HLA-E-and HLA-Ia-restricted T cells (23) , under the experimental conditions described in this work, nearly all of the APC contain at least one Mtb. Hence, we cannot distinguish direct recognition of a Mtb-infected cell from cross-presented Ag. Nonetheless, the dependence on the proteasome and sensitivity to BFA blockade clearly distinguishes our results from those predicted by the detour pathway, and would be consistent with an immunosurveillance role for CD8 ϩ T cells in the control of Mtb. Given evidence supporting three distinct pathways of Ag processing and presentation, we hypothesize that Ags may be processed differentially based upon their physiochemical characteristics. In this study, both of the Ags tested are secreted, of low m.w., and relatively hydrophilic. Hence, it is possible that alternate pathways favor the presentation of hydrophobic or lipidated Ags. Alternately, it is possible that alternate pathways would favor Ags that are rapidly degraded by lysosomally derived proteases. Nonetheless, the availability of Mtb Ags to the cytosolic pathway would support the use of viral vectors as vaccine for Mtb, as we would predict that T cells generated in this context could recognize Mtbinfected cells.
